Cargando…

Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency

BACKGROUND: In recent years, experience on the application of adaptive designs in confirmatory clinical trials has accumulated. Although planning such trials comes at the cost of additional operational complexity, adaptive designs offer the benefit of flexibility to update trial design and objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Collignon, Olivier, Koenig, Franz, Koch, Armin, Hemmings, Robert James, Pétavy, Frank, Saint-Raymond, Agnès, Papaluca-Amati, Marisa, Posch, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245528/ https://www.ncbi.nlm.nih.gov/pubmed/30454061 http://dx.doi.org/10.1186/s13063-018-3012-x

Ejemplares similares

Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency
por: Elsäßer, Amelie, et al.
Publicado: (2014)

The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
por: Cavaleri, Marco, et al.
Publicado: (2021)

Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency
por: Maliepaard, Marc, et al.
Publicado: (2022)

Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?
por: Jaeger, Simon U, et al.
Publicado: (2022)

The Use of Remote Monitoring Technologies: A Review of Recent Regulatory Scientific Advices, Qualification Opinions, and Qualification Advices Issued by the European Medicines Agency
por: Dekker, Marieke J. H. J., et al.
Publicado: (2021)

The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children
por: Kreeftmeijer-Vegter, Annemarie Rosan, et al.
Publicado: (2014)

The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation
por: Ghalandari, N., et al.
Publicado: (2020)

Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union
por: Iglesias-Lopez, Carolina, et al.
Publicado: (2021)

Beyond this world: scientific missions of the European Space Agency
por: Calder, Nigel
Publicado: (1995)

EMEA and Gene Therapy Medicinal Products Development in the European Union
por: Papaluca Amati, Marisa, et al.
Publicado: (2003)

Impact of Amending the Acetylcysteine Marketing Authorisation on Treatment of Paracetamol Overdose
por: Thompson, G., et al.
Publicado: (2013)

Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019)

High Level Group - Scientific Advice Mechanism - European Commission Research and Innovation - European Union
por: Laurine, Mottet
Publicado: (2017)

Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
por: Pontes, Caridad, et al.
Publicado: (2018)

Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?
por: Teixeira, Tania, et al.
Publicado: (2019)

The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis
por: Pelfrene, Eric, et al.
Publicado: (2019)

Experiences and Perspectives of Marketing Authorisation Holders towards Medication Safety Monitoring during Pregnancy: A Pan-European Qualitative Analysis
por: Sillis, Laure, et al.
Publicado: (2022)

Regulatory agencies issue advice on use of NSAIDs for COVID-19
Publicado: (2020)

The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018
por: Schuster Bruce, Catherine, et al.
Publicado: (2019)

An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe
por: Ebbers, Hans C., et al.
Publicado: (2015)

EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
por: Detela, Giulia, et al.
Publicado: (2019)

GANIL authorised
Publicado: (1975)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
por: Tafuri, Giovanni, et al.
Publicado: (2016)

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
por: Ivama-Brummell, Adriana M., et al.
Publicado: (2023)

Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union
por: Hoeve, Christina E., et al.
Publicado: (2019)

Science and Scientific Advice in a Time of Crisis
por: Petersen, Ole H
Publicado: (2020)

Scientific opinion on the renewal of the authorisation of Fumokomp (SF‐009) as a smoke flavouring Primary Product
por: Younes, Maged, et al.
Publicado: (2023)

Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder
por: Agyemang, Elaine, et al.
Publicado: (2017)

EHPnet: European Chemicals Agency
por: Dooley, Erin E.
Publicado: (2008)

Scanning the horizon: a systematic literature review of methodologies
por: Hines, Philip, et al.
Publicado: (2019)

Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients
por: Rohner, Eliane, et al.
Publicado: (2017)

Authorisation for work with electrical equipment
por: Balle, Christoph
Publicado: (2013)

National Association of Authorised Officers
por: Weston, W. H. A.
Publicado: (1952)

Regulatory Scientific Advice on Non-Inferiority Drug Trials
por: Wangge, Grace, et al.
Publicado: (2013)

Supporting Scientific Advice through a Boundary Organization
por: Kennedy, Eric B.
Publicado: (2018)

Regulatory Science and Innovation Programme for Europe (ReScIPE): A proposed model
por: Hines, Philip A., et al.
Publicado: (2019)

Pharmacogenetic‐Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017
por: Maliepaard, Marc, et al.
Publicado: (2020)

Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?
por: Flynn, Robert, et al.
Publicado: (2021)

Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders
por: Mulder, Jorn, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pvdqsfdr4i7ujdo8r97raajc1s